We recently demonstrated that TNFR1 is an interesting drug target by showing that reducing TNFR1 expression by 50% (TNFR1+/− mice) led to total protection against TNF-induced SIRS and TNF-induced intestinal barrier dysfunction (Van Hauwermeiren et al, 2013, 2014). Here, TNFRSF1A is linked to systemic inflammatory response syndrome.